Recommended Dose of Flutamide with LH‐RH Agonist Therapy in Patients with Advanced Prostate Cancer

  title={Recommended Dose of Flutamide with LH‐RH Agonist Therapy in Patients with Advanced Prostate Cancer},
  author={Hideyuki Akaza and Shigeo Isaka and Michiyuki Usami and Hiroshi Kanetake and Toshihiko Kotake and Kenkichi Koiso and Yoshio Aso},
  journal={International Journal of Urology},
Background: In a recent study by the Casodex Combination Study Group, USA, patients in a flutamide (750mg/day) plus LH‐RH agonist group showed a high treatment failure rate, mainly due to flutamide‐induced diarrhea and hepatotoxicity. Our current study was conducted to determine the optimal dose of flutamide for use in this type of Combination therapy. 
[Clinical efficacy of treatment with low-dose flutamide in maximum androgen blockade therapy].
Maximum androgen blockade (MAB) therapy by combining a luteinizing hormone-releasing hormone agonist or orchiectomy with low-dose flutamide is expected to prevent the reduction in the compliance due to side effects and to improve the long-term prognosis in patients with prostate cancer, who are mostly elderly individuals.
Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients.
First-line treatment with bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist is superior to LHRH agonist monotherapy in terms of the antitumor response at 12 weeks, and also time to treatment failure and progression, and does not compromise treatment safety.
Early results of LH-RH agonist treatment with or without chlormadinone acetate for hormone therapy of naive localized or locally advanced prostate cancer: a prospective and randomized study. The Prostate Cancer Study Group.
Early primary hormone therapy is a reasonable treatment option for localized or locally advanced prostate cancer patients if radical prostatectomy was not scheduled and chlormadinone acetate showed an additive effect with LH-RH agonist, at least in 2 years' observation.
Bicalutamide in Advanced Prostate Cancer
Bicalutamide, with its once-daily regimen and good tolerability, is an attractive option when combined with a GnRH agonist in patients with advanced prostate cancer who are suitable to receive maximum androgen blockade regimens.
Receptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activity
This clinical trial of bicalutamide confirms the prediction from preclinical studies that a 50 mg dose of bICALutamide would be appropriate for use in patients with advanced prostate cancer, and demonstrates that this bicalUTamide dose is clinically effective when administered as part of CAB.
Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels
Findings suggest that combination therapy with an LH-RH agonist and CMA is more useful than therapy with the agonist alone in the treatment of prostate cancer.


LH‐RH Agonist, Zoladex (Goserelin), Depot Formulation in the Treatment of Prostatic Cancer Randomized Dose‐Finding Trial in Japan
Endocrine therapy with Zoladex depot in doses of 3.6 mg subcutaneously every 4 weeks is a useful alternative to surgical castration in patients with prostatic cancer, according to the Japanese Prostatic Group Criteria.
[Clinical evaluation of flutamide, a pure antiandrogen, in prostatic cancer phase II dose-finding study].
Determinations of serum hormone levels revealed an increase in testosterone levels by the use of flutamide, which is the optimal dose in monotherapy for hormone-untreated patients with prostatic cancer, where the quality of life can be maintained compared with therapies involving testosterone suppression.
A Randomized Phase II Trial of Flutamide vs Chlormadinone Acetate in Previously Untreated Advanced Prostatic Cancer
Flutamide is as effective as CMA in maintaining libido and potency without decreasing testosterone levels, and is concluded to be as effective in maintaining prostatic cancer patients with no prior experience of hormone therapy.
Long-term clinical study on Luteinising hormone-releasing hormone agonist depot formulation in the treatment of stage D prostatic cancer
LH-RH analogue treatment is thought to be a long-lasting, effective, palliative measure for patients with previously-untreated, advanced, prostatic cancer.
Flutamide monotherapy as primary treatment in advanced prostatic carcinoma.
Flutamide monotherapy was concluded to be relatively safe and effective in patients with advanced prostatic cancer and sexual potency was evaluated in 15 patients, 10 of whom remained sexually active during treatment.
Controversies in the treatment of metastatic prostate cancer
This poster discusses how best to identify and treat prostate cancer in men with a family history of the disease and some of the myths and misconceptions surrounding the disease.
Flutamide hepatotoxicity.
Flutamide is a potent hepatotoxin in certain patients and before beginning use of this drug patients should be instructed to report immediately to physicians any episodes of nausea, vomiting, fatigue and jaundice so that flutamide can be promptly discontinued to avoid progression of possible liver injury.